Latest Investments News

Victor Group Holdings has sharply reduced its FY25 loss to $275,449 from $3.53 million the prior year, while expanding its fintech presence through strategic stakes in LIT Technology and iRich Finance.

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.

Cann Group Limited reported a 34% rise in dried flower production and doubled Botanitech brand flower sales in FY25, while cutting operating expenses by 35%. The company is targeting an EBITDA-positive FY26 amid ongoing debt restructuring.

xReality Group (XRG) reports a landmark FY25 with 36% revenue growth driven by its Operator XR platform and a major US law enforcement contract. The company’s strategic shift towards immersive training technology signals robust momentum into FY26.

Gathid Ltd reported a 142% surge in revenue for FY25 driven by its expanding software business, despite a continuing operations loss and ongoing dispute over the RightCrowd sale proceeds.

xReality Group Limited reported a 36.3% revenue increase to $13.96 million for FY2025, driven by strong Enterprise segment growth, while narrowing its net loss to $3.14 million. Despite challenges in Entertainment revenue and asset pressures, the company maintains a positive cash flow outlook.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.

Ovanti Limited’s FY2025 results reveal a modest revenue dip but a sharp 61% rise in net loss, driven by a significant impairment charge. The company’s capital base strengthened despite ongoing losses, with no dividends declared.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.

ECS Botanics Holdings Ltd reported a $5.7 million net loss for FY2025 amid a strategic pivot from B2B to B2C sales and significant impairments. The company aims for a turnaround in FY2026 driven by new product launches and expanded production capacity.

Aspermont Limited invites existing shareholders to participate in a $1.25 million Share Purchase Plan at a premium price, supporting its pivot to data-driven intelligence services and a strategic Rio Tinto partnership.